Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
HHS-NIH11 Posted PAR-28-042
Close Date:
November 16, 2029
1106 days remaining
Description
The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Actions
Funding Details
- Award Floor
- Not specified
- Award Ceiling
- Not specified
- Total Estimated Funding
- Not specified
- Expected Awards
- Not specified
Key Dates
- Posted
- November 3, 2026
- Closes
- November 16, 2029 1106d
- Archive Date
- January 15, 2030
Agency Information
- Agency Name
- National Institutes of Health
- Agency Code
- HHS-NIH11
- Funding Instrument
- Other